Possible Promise

Make Your Future Promise Possible

You are here: Home / Stock News / J&J’s Stelara Gets EU Nod for Plaque Psoriasis in Children

on Leave a Comment

J&J’s Stelara Gets EU Nod for Plaque Psoriasis in Children

Source: Zacks Investment Research

Johnson & Johnson (JNJ) receives the European Commission’s (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.

Read Full Article

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *